0001104659-21-075903.txt : 20210602 0001104659-21-075903.hdr.sgml : 20210602 20210602191504 ACCESSION NUMBER: 0001104659-21-075903 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20210602 FILED AS OF DATE: 20210602 DATE AS OF CHANGE: 20210602 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Milne Jill C. CENTRAL INDEX KEY: 0001644246 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-37467 FILM NUMBER: 21990791 MAIL ADDRESS: STREET 1: C/O CATABASIS PHARMACEUTICALS, INC. STREET 2: ONE KENDALL SQ., BLDG. 1400E, STE.B14202 CITY: CAMBRIDGE STATE: MA ZIP: 02139 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: CATABASIS PHARMACEUTICALS INC CENTRAL INDEX KEY: 0001454789 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 100 HIGH STREET STREET 2: 28TH FLOOR CITY: BOSTON STATE: MA ZIP: 02110 BUSINESS PHONE: 617-349-1971 MAIL ADDRESS: STREET 1: 100 HIGH STREET STREET 2: 28TH FLOOR CITY: BOSTON STATE: MA ZIP: 02110 4 1 tm2118270-4_4seq1.xml OWNERSHIP DOCUMENT X0306 4 2021-06-02 0 0001454789 CATABASIS PHARMACEUTICALS INC CATB 0001644246 Milne Jill C. C/O CATABASIS PHARMACEUTICALS, INC., 100 HIGH STREET, FLOOR 28 BOSTON MA 02110 1 1 0 0 CEO and President Stock Option (right to buy) 2.87 2021-06-02 4 A 0 1400000 0 A 2031-03-31 Common Stock 1400000 1400000 D Represents the closing price of the common stock of Catabasis Pharmaceuticals, Inc. (the "Company") on April 1, 2021. This option was granted on April 1, 2021 subject to the approval by the stockholders of the Company of an increase in the number of shares of common stock available under the Company's Amended and Restated 2015 Stock Incentive Plan ("Proposal No. 4") at the Company's 2021 Annual Meeting of Stockholders (the "Annual Meeting"). Proposal No. 4 received the requisite approval at the Annual Meeting on June 2, 2021. The option is subject to vesting over a four year period, with 25% of the shares vesting on the first anniversary of April 1, 2021 and the remainder vesting over the ensuing three years at a rate of 2.0833% per month. /s/ Jill C. Milne 2021-06-02